Date: 13-Aug-2019

Senator Grassley seeks info on Novartis Zolgensma data issues

U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its $2 million gene therapy, Zolgensma, by Aug. 23. The Republican, in a letter dated Aug.9 to the drugmakers Chief Executive Officer Vasant Narasimhan, asked the company to provide all records on its internal inquiry into Zolgensma data discrepancies.